Occult Infection with Hepatitis B Virus PreS Variants Synergistically Promotes Hepatocellular Carcinoma Development in a High-fat Diet Context by Generating Abnormal Ceramides

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2022 Sep 4

PMID 36058909

Authors

Chang Liu

Kun Chen

Fei Zhao

Lingling Xuan

Yuting Wang

Chungui Xu

Zhiyuan Wu

Dongmei Wang

Chunfeng Qu

Affiliations

Soon will be listed here.

Abstract

Background: Some occult hepatitis B virus (HBV) infections are resulted from PreS mutations that reduce secretion of envelope protein (HBsAg). We investigated the ceramide amounts and species in hepatocytes infected with PreS variants that were isolated from HBsAg-seronegative patients with hepatocellular carcinoma (HCC) and the ceramide effects on autochthonous HCC development in murine models.

Methods: HBV PreS/S regions from 35 HBsAg-seronegative HCC patients were sequenced. Hepatocyte cell lines and male C57BL/6J mouse livers were transfected with two PreS variant representatives. The ceramides with variated lengths of fatty acyl chains were quantified. Tumour development was examined in the HBV-transfected mice fed different diet types.

Results: In HBsAg-seronegative HCC patients, nonneoplastic liver tissues harboured HBsAg and replication-competent HBV. The most frequently detected PreS/S variants carried mutations of altered amino acid properties in HBsAg compared with an isolate from one HBsAg-seronegative HCC patient. Hepatocyte infection with PreS variants caused HBsAg retention within the endoplasmic reticulum and generated more amounts of ceramides with C16:0 ceramide elevated the highest. Saturated fatty acids aggravated the PreS variant-infected hepatocytes to generate abnormal amounts and species of ceramides, which with HBV proteins synergistically activated NLRP3 inflammasome in liver inflammatory macrophages. Liver tumours were only detected in HBV-transfected mice fed high-fat diet, with higher tumour loads in the PreS variant-transfected, associated with abnormal ceramide generation.

Conclusions: HBV PreS mutations which altered amino acid properties of envelope proteins inhibited HBsAg secretion. Hepatocyte infection with PreS variants generated abnormal ceramides which with HBV proteins coactivated NLRP3 inflammasome in liver macrophages to promote autochthonous HCC development.

Citing Articles

The Characteristic of HBV Quasispecies Is Related to Occult HBV Infection of Infants Born to Highly Viremic Mothers.

Li Y, Song Y, Xiao Y, Wang T, Li L, Liu M Viruses. 2024; 16(7).

PMID: 39066265 PMC: 11281566. DOI: 10.3390/v16071104.

M133S mutation possibly involve in the ER stress and mitophagy pathway in maintenance hemodialysis patients with occult hepatitis B infection.

Zou Y, Chen S, Cui Y, Zou Y Sci Rep. 2024; 14(1):13981.

PMID: 38886481 PMC: 11183135. DOI: 10.1038/s41598-024-64943-3.

Associations between genetic variants in sphingolipid metabolism pathway genes and hepatitis B virus-related hepatocellular carcinoma survival.

Jiang B, Qiu M, Qin L, Tang J, Zhan S, Lin Q Front Oncol. 2024; 13:1252158.

PMID: 38260847 PMC: 10801735. DOI: 10.3389/fonc.2023.1252158.

Machine learning-enhanced insights into sphingolipid-based prognostication: revealing the immunological landscape and predictive proficiency for immunomotherapy and chemotherapy responses in pancreatic carcinoma.

Shi T, Li M, Yu Y Front Mol Biosci. 2023; 10:1284623.

PMID: 38028544 PMC: 10643633. DOI: 10.3389/fmolb.2023.1284623.

Targeting Inflammasome Activation in Viral Infection: A Therapeutic Solution?.

Deng C, Li T, Zhang W, Zhao Q, Wang Y Viruses. 2023; 15(7).

PMID: 37515138 PMC: 10384481. DOI: 10.3390/v15071451.

References

Liu S, Zhang H, Gu C, Yin J, He Y, Xie J . Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009; 101(15):1066-82. PMC: 2720989. DOI: 10.1093/jnci/djp180. View

Azuma M, Ebihara T, Oshiumi H, Matsumoto M, Seya T . Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. Oncoimmunology. 2012; 1(5):581-592. PMC: 3429562. DOI: 10.4161/onci.19893. View

Makarova-Rusher O, Altekruse S, McNeel T, Ulahannan S, Duffy A, Graubard B . Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016; 122(11):1757-65. PMC: 5548177. DOI: 10.1002/cncr.29971. View

Turpin-Nolan S, Bruning J . The role of ceramides in metabolic disorders: when size and localization matters. Nat Rev Endocrinol. 2020; 16(4):224-233. DOI: 10.1038/s41574-020-0320-5. View

Zang M, Li Y, He H, Ding H, Chen K, Du J . IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(12):3759-3770. DOI: 10.1016/j.bbadis.2018.10.004. View

Seeger C, Mason W . Molecular biology of hepatitis B virus infection. Virology. 2015; 479-480:672-86. PMC: 4424072. DOI: 10.1016/j.virol.2015.02.031. View

Pewzner-Jung Y, Brenner O, Braun S, Laviad E, Ben-Dor S, Feldmesser E . A critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathy. J Biol Chem. 2010; 285(14):10911-23. PMC: 2856297. DOI: 10.1074/jbc.M109.077610. View

Maucort-Boulch D, de Martel C, Franceschi S, Plummer M . Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018; 142(12):2471-2477. DOI: 10.1002/ijc.31280. View

Lemmer I, Willemsen N, Hilal N, Bartelt A . A guide to understanding endoplasmic reticulum stress in metabolic disorders. Mol Metab. 2021; 47:101169. PMC: 7887651. DOI: 10.1016/j.molmet.2021.101169. View

10.

Li X, Xie T, Gao L, Ma C, Yang X, Liang X . Prostaglandin E2 facilitates Hepatitis B virus replication by impairing CTL function. Mol Immunol. 2018; 103:243-250. DOI: 10.1016/j.molimm.2018.08.009. View

11.

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok A . Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019; 71(2):397-408. DOI: 10.1016/j.jhep.2019.03.034. View

12.

Zeng J, Qin L, Jin Q, Yang R, Ning G, Su Q . Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary Pancreat Dis Int. 2022; 21(2):154-161. DOI: 10.1016/j.hbpd.2022.01.006. View

13.

Wang M, Wang Y, Feng X, Wang R, Wang Y, Zeng H . Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis. 2017; 65:15-21. DOI: 10.1016/j.ijid.2017.09.003. View

14.

Mridha A, Wree A, Robertson A, Yeh M, Johnson C, Van Rooyen D . NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017; 66(5):1037-1046. PMC: 6536116. DOI: 10.1016/j.jhep.2017.01.022. View

15.

Wang R, Liu C, Chen T, Wang Y, Fan C, Lu L . Neonatal hepatitis B vaccination protects mature adults from occult virus infection. Hepatol Int. 2021; 15(2):328-337. DOI: 10.1007/s12072-021-10156-z. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Zhang X, Goncalves R, Mosser D . The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2008; Chapter 14:14.1.1-14.1.14. PMC: 2834554. DOI: 10.1002/0471142735.im1401s83. View

18.

Zhao L, Liu X, Yan H, Li W, Zeng X, Yang Y . Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun. 2016; 7:12992. PMC: 5059470. DOI: 10.1038/ncomms12992. View

19.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

20.

Xu L, Wei Y, Chen T, Lu J, Zhu C, Ni Z . Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination. Vaccine. 2010; 28(37):5986-92. DOI: 10.1016/j.vaccine.2010.06.106. View